Novavax, Inc. (NASDAQ:NVAX) has been assigned an average recommendation of “Hold” from the twelve brokerages that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, eight have given a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $3.16.

NVAX has been the topic of a number of analyst reports. Citigroup Inc. raised shares of Novavax from a “neutral” rating to a “buy” rating and set a $2.00 price objective on the stock in a research note on Tuesday, October 31st. Zacks Investment Research raised shares of Novavax from a “hold” rating to a “buy” rating and set a $1.25 price objective on the stock in a research note on Wednesday, August 16th. Ladenburg Thalmann Financial Services raised shares of Novavax from a “neutral” rating to a “buy” rating and set a $1.60 price objective on the stock in a research note on Wednesday, August 9th. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $1.50 price objective on shares of Novavax in a research note on Wednesday, July 26th. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and issued a $2.00 price objective on shares of Novavax in a research note on Friday, July 21st.

In related news, Director James F. Young sold 175,000 shares of the stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $1.06, for a total transaction of $185,500.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 4.00% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of NVAX. Wells Fargo & Company MN boosted its stake in Novavax by 2.7% during the first quarter. Wells Fargo & Company MN now owns 343,714 shares of the biopharmaceutical company’s stock worth $440,000 after acquiring an additional 8,966 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Novavax by 0.9% during the first quarter. Bank of New York Mellon Corp now owns 1,215,100 shares of the biopharmaceutical company’s stock worth $1,555,000 after buying an additional 10,347 shares during the last quarter. American International Group Inc. raised its holdings in Novavax by 7.1% during the first quarter. American International Group Inc. now owns 166,252 shares of the biopharmaceutical company’s stock worth $213,000 after buying an additional 10,965 shares during the last quarter. Vanguard Group Inc. raised its holdings in Novavax by 4.5% during the first quarter. Vanguard Group Inc. now owns 21,681,318 shares of the biopharmaceutical company’s stock worth $27,752,000 after buying an additional 938,581 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in Novavax by 18.3% during the first quarter. Geode Capital Management LLC now owns 2,400,960 shares of the biopharmaceutical company’s stock worth $3,073,000 after buying an additional 371,295 shares during the last quarter. 44.85% of the stock is currently owned by institutional investors and hedge funds.

Shares of Novavax (NVAX) remained flat at $$1.13 during midday trading on Friday. 2,276,663 shares of the company were exchanged, compared to its average volume of 5,938,529. The company has a debt-to-equity ratio of -4.28, a current ratio of 3.31 and a quick ratio of 3.54. Novavax has a 1-year low of $0.73 and a 1-year high of $1.78.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.16) by $0.01. Novavax had a negative net margin of 726.35% and a negative return on equity of 787.38%. The firm had revenue of $8.35 million during the quarter, compared to analysts’ expectations of $6.42 million. During the same period in the prior year, the company posted ($0.24) EPS. The company’s revenue was up 158.5% on a year-over-year basis. equities research analysts predict that Novavax will post -0.62 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Brokerages Set Novavax, Inc. (NVAX) PT at $3.16” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.thecerbatgem.com/2017/11/10/brokerages-set-novavax-inc-nvax-pt-at-3-16.html.

About Novavax

Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.

Analyst Recommendations for Novavax (NASDAQ:NVAX)

Receive News & Stock Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related stocks with our FREE daily email newsletter.